利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.044 秒)

    Modified factor VII
    2.
    发明授权
    Modified factor VII 失效
    修饰因子VII

    公开(公告)号：US06168789A

    公开(公告)日：2001-01-02

    申请号：US09189607

    申请日：1998-11-10

    申请人： Kathleen L. Berkner ,  Lars Christian Petersen ,  Charles E. Hart ,  Ulla Hedner ,  Claus Bregengaard

    发明人： Kathleen L. Berkner ,  Lars Christian Petersen ,  Charles E. Hart ,  Ulla Hedner ,  Claus Bregengaard

    IPC分类号： A61K3848

    CPC分类号： C12N9/6437 ,  A61K38/166 ,  A61K38/4846 ,  A61K38/49 ,  C12Y304/21021 ,  Y10S514/802 ,  A61K2300/00

    摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.

    摘要翻译： 因子VII的催化活性位点被修饰以产生有效中断凝血级联的化合物。 修饰使得因子VIIa基本上不能激活血浆因子X或IX。 修饰因子VII的药物组合物用于治疗各种凝血相关疾病，包括血小板沉积，血管血栓形成，缺血再灌注，冠状动脉急性闭合，继发于球囊血管成形术的血管再狭窄，内膜切除术，还原性粥样斑块切除术，支架置入 ，激光治疗或旋转消融。

    Modified factor VII
    6.
    发明授权
    Modified factor VII 失效
    修饰因子VII

    公开(公告)号：US06183743B2

    公开(公告)日：2001-02-06

    申请号：US09378907

    申请日：1999-08-20

    申请人： Charles E. Hart ,  Lars C. Petersen ,  Ulla Hedner ,  Mirella E. Rasmussen

    发明人： Charles E. Hart ,  Lars C. Petersen ,  Ulla Hedner ,  Mirella E. Rasmussen

    IPC分类号： A61K3848

    CPC分类号： A61K38/4846 ,  Y10S514/802

    摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.

    摘要翻译： 因子VII的催化活性位点被修饰以产生有效中断凝血级联的化合物。 修饰使得因子VIIa基本上不能激活血浆因子X或IX。 本发明涉及新的治疗方法和修饰因子VII用于预防或治疗与缺血后再灌注相关的心肌损伤，用于改善再灌注期间的局部心肌血流量，以及维持或改善患者血管通畅以及局部 在血栓形成易感的血管部位应用修饰的因子VII。

    Modified factor VII
    7.
    发明授权
    Modified factor VII 失效
    修饰因子VII

    公开(公告)号：US5997864A

    公开(公告)日：1999-12-07

    申请号：US871003

    申请日：1997-06-06

    申请人： Charles E. Hart ,  Lars C. Petersen ,  Ulla Hedner ,  Mirella E. Rasmussen

    发明人： Charles E. Hart ,  Lars C. Petersen ,  Ulla Hedner ,  Mirella E. Rasmussen

    IPC分类号： A61K38/48 ,  A61K35/14 ,  C12N9/48 ,  C12N9/64

    CPC分类号： A61K38/4846 ,  Y10S514/802

    摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.

    摘要翻译： 因子VII的催化活性位点被修饰以产生有效中断凝血级联的化合物。 修饰使得因子VIIa基本上不能激活血浆因子X或IX。 本发明涉及新的治疗方法和修饰因子VII用于预防或治疗与缺血后再灌注相关的心肌损伤，用于改善再灌注期间的局部心肌血流量，以及维持或改善患者血管通畅以及局部 在血栓形成易感的血管部位应用修饰的因子VII。